Trials / Completed
CompletedNCT05427162
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
Open-Label, Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Different Formulations of an IP Receptor Agonist
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prostacyclin Receptor Agonist | Prostacyclin receptor agonist will be administered. |
Timeline
- Start date
- 2022-06-21
- Primary completion
- 2023-12-05
- Completion
- 2023-12-05
- First posted
- 2022-06-22
- Last updated
- 2025-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05427162. Inclusion in this directory is not an endorsement.